Navigation Links
PharmaNet Development Group Agrees to be Acquired by JLL Partners
Date:2/3/2009

this transaction provides meaningful value to our stockholders while providing the solution to address the outstanding convertible notes."

"PharmaNet Development Group is well-positioned as a leading provider of outsourced clinical development services with a global infrastructure and an excellent reputation," said Ramsey Frank, Managing Director of JLL. "We look forward to working with the management team to enhance the Company's growth prospects and expand its portfolio of services."

The Merger Agreement provides for JLL to acquire PharmaNet in a two-step transaction. The first step will consist of a cash tender offer for all outstanding shares of PharmaNet common stock at a price of $5.00 per share in cash. In the second step, the tender offer will be followed by a merger in which any untendered outstanding shares of PharmaNet common stock will be converted into the right to receive the same cash price per share paid in the tender offer.

UBS Investment Bank is acting as exclusive financial advisor to PharmaNet, and Morgan, Lewis & Bockius, LLP is acting as PharmaNet's legal counsel in the transaction. Latham & Watkins LLP is acting as legal counsel in the transaction to the PharmaNet Board of Directors.

Skadden, Arps, Slate, Meagher & Flom LLP is acting as JLL's legal counsel in the transaction.

About PharmaNet Development Group, Inc.

PharmaNet Development Group, Inc., a global drug development services company, provides a comprehensive range of services to the pharmaceutical, biotechnology, generic drug and medical device industries. The Company offers early and late stage consulting, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs. With approximately 2,500 employees and 41 facilities throughout the world, PharmaNet is a recognized leader in outsourced clinical dev
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. SemBioSys updates Apo AI development program
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... COSTA MESA, Calif. , July 24, 2014 /PRNewswire/ ... incredibly close to home. Rehealth Regenerative Therapies , ... offering athletes and other physically active people a new ... . Regardless of age, countless patients suffer ... amateur sport activities, such as muscle tears, torn rotator ...
(Date:7/24/2014)... 2014  Asterias Biotherapeutics, Inc. (OTCBB: ASTYV), a ... regenerative medicine, announced today that it will host ... on Tuesday, July 29, 2014, at 4:30 p.m. ... an overview of Asterias, business strategy and product ... http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 minutes before the ...
(Date:7/24/2014)...  ECC West Africa, LLC (ECC) signed a contract ... College Hospital (UCH) Ibadan Board of Management for the ... construct, and operate and maintain a new, state-of-the-art Cancer ... the first of the 4-phase project, ECC will conduct ... UCH Ibadan intends to finance and develop the Cancer ...
(Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... 18 eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), ... ePRO and other services to the pharmaceutical,biotechnology, medical ... J. McKelvey, the Company,s President and Chief Executive,Officer, ... are,scheduled to present at the UBS Global Life ...
... TORONTO, Sept. 18 /PRNewswire-FirstCall/ - ARIUS Research Inc., ... next wave of,antibody therapeutics, today announced that ARIUS ... plan of arrangement,involving the Company and Roche., ... September 16, 2008, ARIUS,shareholders and warrant holders approved ...
... Quick Traction in the Region, FREDERICK, Md., Sept. ... sales agent it announced,last week, Abdulkader Al-Mehyar Moh,d Basheer ... the Middle Eastern region., "We are pleased that ... is,finding wide marketing acceptance for our products. We look ...
Cached Biology Technology:eResearchTechnology, Inc. to Present at the UBS Global Life Sciences Conference on September 23rd, 2008 2ARIUS sale approved by shareholders 2BioElectronics Corp. Announces $400,000 in New Orders From the Middle East 2
(Date:7/24/2014)... 2014 /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative ... cut emergency room wait times by an average of ... Center, according to a recent study published in the ... using the suite to access data from incoming patients, ... "Using Geneva,s technology platform we have been able ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... species for food or commercial food sale, has been ... decline of many species of primates and other mammals. ... half of the species being consumed are birds, particularly ... only the meat made available for sale but the ... hunters and brought to villages for consumption, we noted ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
... the body's motor nerve cells grow along proper paths ... inhibiting spinal-cord neurons from regenerating after injury, researchers at ... the researchers found that a component of myelin ?a ... in adult vertebrates ?chemically blocks the ability of nerve ...
... for the first time that bacteria, in addition to ... sparkling wine known as Cava. They report their findings ... Society for Microbiology. , "Bacteria found in Cava samples ... in terms of aroma, flavor, bubble size and bubble ...
... hanging basket style device is at the heart of a plan ... sex drive of a major pest of fruit ... that very same pest. The device allows growers to selectively ... killing other beneficial insects. , The researchers at Warwick HRI, the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3After the yeast is gone bacteria continue to develop flavor of sparkling wine 2Hanging baskets of sex and death help fruit growers 2
RECK (F-20)...
... This adapter allows ... (AB-0800 and AB-1000) PCR ... in the ABI PRISM® ... contact ABgene® for information ...
... Eliminates nonspecific products due to inactivity ... allows extension through DNA regions which contain ... an 'A' overhang ,TEMPase II is ... Polymerase that remains inactive at room ...
... solution. Cleaves a-(1-3)- and ... and glycoproteins. It is particularly efficient for ... pH must be neutral or above, for ... Unit Definition: One unit will hydrolyze ...
Biology Products: